DOI:

Elixir Medical’s bioresorbable drug eluting stent (BDES) programme: an overview

John Yan, MS; Vinayak D. Bhat*, PhD

Introduction

The use of a non-permanent versus temporary/degradable implant to treat coronary vascular disease has been an attractive concept since the advent of percutaneous coronary revascularisation with balloon angioplasty and stenting. An ideal bioresorbable stent would provide mechanical support to the blood vessel wall for a sufficient period of time and bioerode into components which are eliminated from the human body leaving behind an open and functional blood vessel. Bioresorbable polymeric stents can release anti-proliferative or anti-inflammatory drugs to control intimal hyperplasia caused by the interventional procedure. These stents would be MRI compatible, could facilitate re-intervention by percutaneous or surgical means and may also have the potential to reduce late stent thrombosis due to the absence of a permanent implant.

One of the challenges in developing a polymeric resorbable stent is its ability to provide sufficient strength to the vessel over a sufficient period of time. In addition, ease of use of the bioresorbable stents should be similar to conventional metallic stents as well.

The Igaki-Tamai® stent1 was the first fully bioresorbable stent to be used clinically, and was made from poly(L-lactide) or PLLA. The PLLA stent required heating to 50°C during balloon expansion. Since then, PLLA have been employed by companies such as Abbott Vascular to allow expansion of bioresorbable stents at body temperature. In addition, companies like Cordis, Biosensors, Tepha and Orbus Neich have used PLLA to allow stent expansion at body temperature2. Non-lactide based polymers such as tyrosine-derived polycarbonate stents have also been developed for use in bioabsorbable stents from the collaboration of Rutgers University (Rutgers, NJ, USA) and REVA Medical (San Diego, CA, USA).

Elixir Medical bioresorbable drug eluting stent (BDES)

The bioresorbable stent of Elixir Medical Corporation (Sunnyvale, CA, USA) is developed to address the needs of balancing the competing requirements of the temporary implant to provide a “no compromise” system.

Stent material

Elixir utilises PLLA as its base polymer material. PLLA has an extensive history of use in medical applications including uses in orthopaedics, cardiology and medical sutures. Elixir is extensively evaluating means to control polymer material properties such as strength, recoil and degradation profile as well as using proprietary fabrication and processing technologies to enable expansion of the stent at physiological temperature with minimal recoil and optimised radial strength. Based on these processes, the Elixir BDES stent is expected to biodegrade and resorb over a period of 2-3 years. The resorption of these polymers occurs mainly by hydrolysis and begins with loss in molecular weight or decreases in the number of repeating monomer units followed by loss in strength and mass. This produces by-products which are metabolised into pyruvic acid required for the Krebs Cycle. It is ultimately excreted from the body as carbon dioxide and water3.

Pharmaceutical agent

Elixir Medical has multiple pharmaceutical agents in its drug product portfolio. Elixir developed Novolimus™, a novel mTOR inhibitor macrocyclic lactone, with antiproliferative and anti-inflammatory properties, for drug eluting stent applications. Elixir has an exclusive worldwide license for use of Myolimus in fully biodegradable stents. Myolimus™ is a novel mTOR inhibitor macrocyclic lactone with a broad therapeutic index and an excellent stability profile which makes it desirable for BDES applications.

BDES stent platform & delivery system

Multiple stent designs have been evaluated in the Elixir BDES program, including the samples depicted in Figure 1. Elixir’s rapid exchange delivery system is composed of a stainless steel hypotube proximal shaft, nylon blend distal shaft, and nylon blend balloon material. Figure 2 shows a sample BDES stent on a stent delivery system both in the crimped and expanded states.

Figure 1. Sample stent designs with radioapaque markers (centre) evaluated in the Elixir BDES program.

Figure 2. Sample stent pre-mounted on a 3.0mm delivery system in crimped and deployed states.

A summary of the stent technical specifications is provided below:

Material composition: PLLA-based polymer

Radiopaque markers: Markers at proximal and distal ends

Degree of radiopacity: Moderate with markers

Ferro-magnetism: Non-ferromagnetic (MRI compatible)

Deployment mechanism: Balloon expandable

Minimum internal diameter

of guiding catheter: 0.075 inch (1.9 mm), 7 Fr

BDES radial strength

Compressive radial strength of sterilised stents was measured using a low friction iris-type radial compression tester connected to a tensile tester. The devices were exposed to a 37°C circulating water bath, expanded to the intended diameter and then inserted into the radial compression fixture which was also in a 37°C water bath; a circumferential compressive force was then applied. The radial compression fixture was actuated at a controlled rate by a tensile test stand such that the force vs diameter change were measured, and a force-displacement curve generated. The force-displacement curve was used to calculate the stent stiffness (modulus) and the force required to resist 15% diameter compression. Compressive radial strength for different stent designs as compared to Elixir’s bare metal alloy stent are presented in Figure 3.

Figure 3. Compressive radial strength of Elixir BDES prototypes with different design and processing parameters compared to Elixir’s bare metal cobalt-chromium alloy stent (BMS).

BDES recoil

Similarly, recoil testing of sterilised stents was conducted by expanding the stent to nominal diameter in a 37°C circulating water bath. The stent diameter was measured using an optical comparator and inspected for evenness of expansion and stent integrity. The balloon was then deflated and the stent maintained in the water bath for one hour before the diameter was re-measured. Changes in diameter were noted, and the amount of recoil was calculated based on initial diameter vs final diameter at one hour. The change in expanded diameter recorded as percentage recoil for different stent designs as compared to Elixir’s bare metal alloy stent are presented in Figure 4.

Figure 4. Percentage recoil of Elixir BDES prototypes with different design and processing parameters compared to Elixir’s bare metal cobalt-chromium alloy stent (BMS).

The radial strength and recoil data suggests that stent design and material processing parameters play a significant role in the mechanical performance of the BDES stent, and in fact, the mechanical properties of the BDES can be comparable to bare metal stents.

Elixir has initiated preclinical testing of the polymer only resorbable stent and multiple BDES prototypes in the porcine coronary artery model to evaluate the biological response to stent implantation over different periods of time. Additional drug pharmacokinetic studies and bioresorption studies of the stent material are also ongoing.

Conclusion

Elixir Medical is developing a PLLA based fully bioresorbable stent with mechanical properties and delivery system performance similar to currently available metallic stent platforms. Preclinical studies are ongoing to evaluate the biological response, pharmacokinetics and bioresorption profile of the stent in a porcine coronary artery model. Upon successful completion of these studies, Elixir will evaluate the BDES in a FIM clinical trial.

Volume 5 Supplement F
Dec 30, 2009
Volume 5 Supplement F
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00037 Sep 1, 2025
Angina and coronary microvascular dysfunction: unravelling the links
Berry C and Hanna R
free

Editorial

10.4244/EIJ-E-25-00045 Sep 1, 2025
Angiographic-based assessment of microvascular dysfunction: quo vadis?
Bourantas C et al
free

Original Research

10.4244/EIJ-D-25-00277 Sep 1, 2025
Chest pain patterns and coronary microvascular function in non-obstructive coronary artery disease
Nogami K et al

Original Research

10.4244/EIJ-D-24-00952 Sep 1, 2025
Single-view angiographic microcirculatory resistance index after primary PCI: the EARLY-MYO-AMR study
Zhang Z et al
open access

Original Research

10.4244/EIJ-D-25-00349 Sep 1, 2025
A preclinical study of combined hepatic and renal artery denervation
Mahfoud F et al

Research Correspondence

10.4244/EIJ-D-25-00147 Sep 1, 2025
A Bayesian analysis of invasive treatment strategies for elderly patients with acute coronary syndromes
Siontis G and Efthimiou O

Flashlight

10.4244/EIJ-D-24-01022 Sep 1, 2025
Tip-in balloon grenadoplasty for uncrossable chronic total occlusions
Achim A and Cocoi M

Letter to the editor

10.4244/EIJ-D-25-00463 Sep 1, 2025
Letter: When gradients diverge: integrating invasive assessment into post-TAVI surveillance
Skalidis I et al
Trending articles
95.75

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
76.8

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
62.15

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.2

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.1

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
28.25

Clinical research

10.4244/EIJ-D-19-01006 Aug 7, 2020
Coronary collaterals and myocardial viability in patients with chronic total occlusions
Schumacher S et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved